Clinical Research Papers:
Laparoscopic sleeve gastrectomy versus Roux-en-Y gastric bypass for morbid obesity: a 1:1 matched cohort study in a Chinese population
PDF | HTML | How to cite
Metrics: PDF 1649 views | HTML 2203 views | ?
Xiao Du1,*, Si-qin Zhang2,*, Hong-xu Zhou1, Xue Li1, Xiao-juan Zhang2, Zong-guang Zhou1 and Zhong Cheng1
1 Department of Gastrointestinal Surgery, Laboratory of Bariatric and Metabolic Surgery, West China Hospital, Sichuan University, Chengdu, P.R. China
2 Department of Endocrinology and Metabolism, West China Hospital, Sichuan University, Chengdu, P.R. China
* These authors have contributed equally to this study
Zhong Cheng, email:
Keywords: bariatric surgery; Roux-en-Y gastric bypass; sleeve gastrectomy; morbid obesity; weight loss
Received: August 17, 2016 Accepted: October 05, 2016 Published: October 08, 2016
Objectives: This 1:1 matched cohort study with 3-year follow-up aimed to compare the safety and efficacy of LSG with LRYGB for morbid obesity patients.
Methods: From 2009 to 2013, patients undergoing LRYGB (n = 63) were matched with LSG (n = 63) by gender, age, and body mass index (BMI). Major complications, BMI, percentage of excess weight loss (%EWL), and obesity-related comorbidities after 6, 12, 24, and 36 months were compared.
Results: Hospital stay and major complication rates were comparable, but operative time in LSG was significantly shorter (83.2 ± 23.7 vs. 108.3 ± 21.3 min). No significant differences in mean %EWL and BMI were observed at 6, 12, 24 months. At 3-year follow-up, mean %EWL in the LRYGB group was significantly higher than in the LSG group (76.5 ± 9.2% vs. 65.7 ± 10.3%) and, consequently, mean BMI was significantly lower in LRYGB (28.2 ± 1.5 vs. 30.9 ± 2.4 kg/m2). No significant differences in remission of comorbidities were observed at 1- or 3-year follow-up.
Conclusions: Both LRYGB and LSG were safe and effective bariatric procedures in this Chinese population, but LRYGB seemed to be superior to LSG in terms of mid-term weight loss.
All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.